Rhumbline Advisers Puma Biotechnology, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 46,628 shares of PBYI stock, worth $146,411. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,628
Previous 50,270
7.24%
Holding current value
$146,411
Previous $163,000
27.61%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding PBYI
# of Institutions
101Shares Held
29MCall Options Held
50.6KPut Options Held
16.3K-
Vanguard Group Inc Valley Forge, PA3.64MShares$11.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$11.2 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$9.62 Million0.42% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.88MShares$9.05 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$6.18 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $143M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...